Viewing nowPelojeong 5 mg (Memantine Hydrochloride)
Memantine Hydrochloride 5mg
Tablet · Prescription medication
Myeongin Pharmaceutical Co., Ltd.

MFDS item code 202003712 · Approved 2020.05.21 · Insurance code 651904960
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease. It helps alleviate symptoms related to cognitive decline in patients, thereby easing difficulties in daily life. With consistent use, it can delay the deterioration of memory and cognitive abilities. This drug contributes to improving the quality of life for patients and their families. Because of these characteristics, it is recommended as a suitable treatment for patients with severe Alzheimer's.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only if a caregiver is able to regularly monitor the patient's medication use. Diagnosis should be made in accordance with currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be reassessed regularly. This medicine is administered orally once daily, at the same time each day. If necessary, this medicine may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (days 1-7) Administer 5mg daily for 7 days. Week 2 (days 8-14) Administer 10mg daily for 7 days. Week 3 (days 15-21) Administer 15mg daily for 7 days. Starting week 4 Administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Elderly patients: Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg daily. 3. Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated, the dose may be increased to 20mg daily according to the standard dose titration schedule after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.
This medication should not be administered to patients who have had an allergic reaction to any of its components. It should also be avoided in patients with severely impaired liver function or very poor kidney function. Additionally, this medication contains lactose, so individuals with a genetic disorder that prevents them from digesting lactose should not take it. Patients with epilepsy or a history of seizures should use this medication cautiously, as side effects may worsen when taken with certain drugs. Patients with changes in urine acidity or recent heart-related disorders should also exercise caution when using this medication. During use, symptoms such as dizziness, headache, constipation, drowsiness, and hypertension may occur; thus, if any abnormal symptoms appear, consult a physician. This medication may interact with other drugs, particularly those affecting the central nervous system, so it is essential to follow a specialist's guidance when taking them together. Women who are pregnant or breastfeeding should consult a doctor before taking this medication, and it is advisable to discontinue breastfeeding if possible. It is preferable not to use this medication in children or adolescents under 18 years of age, as safety and efficacy have not been established. In cases of overdose, central nervous system symptoms or digestive symptoms may appear; immediate medical attention is required in such cases. This medication may decrease the patient's reaction speed and concentration, so caution is advised when driving or operating machinery. Finally, store this medication out of reach of children and do not transfer it to another container for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container that prevents air and moisture from entering, at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness.
Pale yellow round film-coated tablets
30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 5mg
Tablet · Prescription medication
Myeongin Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.